GLP-1
US$ 29.18
glp-1 receptor agonist news Agonists as Treatments for Type 2 Diabetes History of glucagon-like peptide-1 receptor
Description
The Asia Pacific GLP-1 industry is projected to record the highest growth rate during the forecast period
In phase III trials, these agents have demonstrated an average A1C decrease of about 0.5% when administered as monotherapy
This content is not medical advice
I 2 = 6
Evolution of mitochondria as signaling organelles
Within this metabolic context, GLP-1RA therapy may create conditions in which reliance on lipid-derived substrates increases the functional importance of redox-buffering systems that maintain oxidative stability
